Sunday, March 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Unvaccinated kids can stay in school after exposure if tested, CDC says

With a potential surge in COVID-19 cases in the coming weeks, the Biden administration pressed its new strategy to reduce the time unvaccinated children miss in school after a virus exposure.

Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention, said the “test to stay” strategy would increase testing of children and their close contacts after an exposure to someone who has tested positive for COVID-19 in order to prevent the child from having to isolate at home and miss time in class.

The new guideline allows unvaccinated children to remain in school after an exposure under certain circumstances, including undergoing multiple tests. For children to remain in school, two negative tests within a week after the exposure are required.

Source: USA Today

https://www.usatoday.com/story/news/health/2021/12/17/covid-vaccine-mandate-cases-health-care-workers/8933003002/

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

2027 Medicare Advantage & Part D Advance Notice

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!